Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Arcturus reported financial results for the quarter ended September 30, 2026.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Arcturus reported financial results for the quarter ended September 30, 2026
- Corporate update covers ARCT-032, ARCT-810, ARCT-2601 and the LUNAR 2.0™ platform
- Key catalysts include ARCT-032 Phase 2 completion, potential Phase 3 decision and ARCT-2601 initial dosing
- Pipeline outlook also includes PKU IND planning, myNEO acquisition benefits and KOSTAIVE® EU and UK launch plans
- Detailed financial results and corporate updates appear in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $18.3M, up from $17.2M, boosted by the $12.0M CSL Seqirus termination payment
- Cash $184.8M, down $46.1M from December 31, 2025, with management projecting runway through year-end 2028
- Net loss $7.4M, or $0.26 per share, versus $13.4M, or $0.49, in Q3 2025
- ARCT-032 Phase 2 enrollment targeted for completion by year-end 2026, with data presentation planned for Q2 2027
- ARCT-2601 Phase 2 dosing planned for Q1 2027, with top-line data expected in H2 2027 and LUNAR 2.0 showing 38-fold greater potency preclinically
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.